Press releases

RaySearch and Mevion announce strategic partnership

RaySearch and Mevion to develop advanced treatment planning solutions for the Mevion S250 with HYPERSCAN. Collaboration to benefit from RayStation’s advanced planning capabilities and HYPERSCAN’s fast pencil beam scanning proton therapy technology

RaySearch Laboratories AB and Mevion Medical Systems, Inc., two companies that are leading the field of proton therapy, are announcing a partnership to develop advanced treatment planning solutions for the MEVION S250 proton therapy platform. RaySearch’s RayStation® treatment planning system supports the MEVION S250’s current configuration so this new partnership will focus on validating the use of the RayStation® treatment planning system for Mevion’s new HYPERSCAN pencil beam scanning technology, and developing advanced planning solutions that take advantage of HYPERSCAN’s rapid pencil beam delivery capabilities.

“Mevion and RaySearch are leaders in the proton therapy marketplace and it is only natural that we would collaborate,” said Joseph K. Jachinowski, President and CEO of Mevion Medical Systems. “By partnering, we are creating a synergy that allows clinicians to maximize the benefits of our technologies and realize the full potential of HYPERSCAN’s fast pencil beam scanning delivery.”

Johan Löf, President and CEO of RaySearch Laboratories AB said: “We are excited to collaborate with Mevion to combine the powerful treatment planning tools in RayStation with the HYPERSCAN technology. Together we will help deliver advanced cancer care to the patients who need it most.”

The partnership is being announced at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco. More information is available at the Mevion booth 728 and the RaySearch booth 2315

HYPERSCAN’s patented technology, paired with the direct and efficient proton beam generation of the MEVION S250 platform, allows tumor volumes to be quickly scanned in a matter of seconds. This speed makes HYPERSCAN’s treatment delivery much less sensitive to patient and tumor motion.

HYPERSCAN has not been cleared by the USFDA for clinical use. 

About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion’s flagship product, the MEVION S250 proton therapy platform, is the only modular, single room proton therapy system currently on the market. The MEVION S250 integrates with standard radiation therapy workflow and provides a proton therapy treatment environment at a fraction of the cost, footprint and operational complexity of conventional systems.

Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. For more information, please visit

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30